EPITALON Epitalon Peptide Therapy in Connecticut Evidence-informed peptide care for healthy aging, sleep, and vitality
CagriSema combines two proven mechanisms (amylin + GLP-1) in a fixed-dose injection, achieving 20.4% weight loss in Phase 3, with an NDA already filed and the advantage of building on the well-characterized semaglutide platform
Learn the difference between low SAM, high SAH and other impediments to methylation
6, 7 From 70% to 80% of genotype 2- and 3-infected patients achieve an SVR
The activation of two transcription factors, aryl hydrocarbon receptor (AhR, which is sensitive to ROS) and hypoxia-inducible factor (HIF)-1, which is responsive to the TCA metabolites succinate, were associated with an increase in IL-22 production